Curanex Pharmaceuticals (CURX) closed at $6.09 on November 10, 2026, down 1.8% from the previous close, on volume of 1,943 shares (30-day average 16,591).
Data as of November 10, 2026.
No press releases found.
Market Chameleon (Thu, 26-Feb 4:53 AM ET)
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
Curanex Pharmaceuticals trades on the NASDAQ stock market under the symbol CURX.
As of November 10, 2026, CURX stock price declined to $6.09 with 1,943 million shares trading.
CURX has a beta of 0.22, meaning it tends to be less sensitive to market movements. CURX has a correlation of 0.00 to the broad based SPY ETF.
CURX has a market cap of $9.55 million. This is considered a Sub-Micro Cap stock.
CURX has underperformed the market in the last year with a return of -48.0%, while SPY returned +11.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CURX shares. However, CURX has outperformed the market in the last 3 month and 2 week periods, returning +57.4% and +27.8%, while SPY returned -2.7% and -2.6%, respectively. This indicates CURX has been having a stronger performance recently.
CURX support price is $5.55 and resistance is $6.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CURX shares will trade within this expected range on the day.
